Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Hansa Biopharma AB's share price for the quarter that ended in Mar. 2024 was kr29.1. Hansa Biopharma AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 52.7 Mil. Therefore, Hansa Biopharma AB's market cap for the quarter that ended in Mar. 2024 was kr1,532.7 Mil.
Hansa Biopharma AB's quarterly market cap
declined
from Sep. 2023 (kr1,804.1 Mil) to Dec. 2023 (kr1,380.0 Mil) but then
increased
from Dec. 2023 (kr1,380.0 Mil) to Mar. 2024 (kr1,532.7 Mil).
Hansa Biopharma AB's annual market cap
declined
from Dec. 2021 (kr3,949.2 Mil) to Dec. 2022 (kr2,581.3 Mil) and
declined
from Dec. 2022 (kr2,581.3 Mil) to Dec. 2023 (kr1,380.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hansa Biopharma AB's Enterprise Value for Today is kr2,805.2 Mil.
Hansa Biopharma AB Market Cap Historical Data
The historical data trend for Hansa Biopharma AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hansa Biopharma AB's Market Cap
For the Biotechnology subindustry, Hansa Biopharma AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Market Cap falls into.
Hansa Biopharma AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Hansa Biopharma AB's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hansa Biopharma AB Market Cap Related Terms
Thank you for viewing the detailed overview of Hansa Biopharma AB's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Hansa Biopharma AB (OSTO:HNSA) Business Description
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:HNSA has been successfully added to your 